Current Report Filing (8-k)
November 09 2016 - 9:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 9, 2016
Aquinox Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36327
|
|
98-0542593
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
450 - 887 Great Northern Way,
Vancouver, B.C.
Canada,
V5T 4T5
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code: (604) 629-9223
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02 Results of Operations and Financial Condition
On November 9, 2016, Aquinox Pharmaceuticals, Inc. (the Company) issued a press release announcing financial results for the third quarter ending
September 30, 2016. The full text of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this current report on Form 8-K and the press release attached as Exhibit 99.1 hereto is being furnished, but shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits
|
|
|
Number
|
|
Description
|
|
|
99.1
|
|
Press Release of Aquinox Pharmaceuticals, Inc. dated November 9, 2016
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
|
Aquinox Pharmaceuticals, Inc.
|
|
|
By:
|
|
/s/ Kamran Alam
|
Name:
|
|
Kamran Alam
|
Title:
|
|
Chief Financial Officer
|
Date: November 9, 2016
INDEX TO EXHIBITS
|
|
|
Number
|
|
Description
|
|
|
99.1
|
|
Press Release of Aquinox Pharmaceuticals, Inc. dated November 9, 2016
|
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
From Apr 2023 to Apr 2024